Various types of stem cells were used to facilitated drug discovery. Based on their own unique characteristics, these cells can be applied in the research setting for a plethora of uses. They can be potentially used as the disease models to treated or cure many life-threatening or chronic illnesses. Human embryonic stem cells (ESC) may store the genetic information which may be discovering how some diseases develop. Also, the human stem cells are being used to test new drugs. By using stem cells, not only the process of drug research and its subsequent path to becoming an approved drug can be accelerated, but also the potential side effects of the drug before it is tested on humans can be revealed. Cells taken from a patient, another approach, with a genetic disease can be reprogrammed as human induced pluripotent stem cells (iPSCs) which is one of the most important developments in disease modeling. They are functionally equivalent to ESCs, and they can subsequently be differentiated into disease-relevant cell types to uncover molecular and cellular mechanisms and to screen for drug treatment options. Modeling the disorders with mild or complex phenotypes can be achieved by reprogramming process used to create the iPSCs, as known as variability. As a result, by performing targeted gene knock-outs, the tissue-specific cell lineage was generated, by overexpressing genes from defined genome location, the point mutations can be introduced. Consequently, the disease-relevant mutation can be discovered by the phenotypes identified in these cells.
According to the mechanisms which closely recapitulate the in vivo microenvironment, applying the stem cells for drug discovery can directly influence drug design and clinical strategies. At Creative Biolabs, various types of stem cells were used to facilitated drug discovery. Based on their own unique characteristics, these cells can be applied in the research setting for a plethora of uses. We provide two different stem cell facilitated drug discovery services. The stem cell-based disease modeling service which including the disease of Alzheimer's disease, Parkinson's disease, Zika Virus infection, Hepatic disorder, Spinal muscular atrophy, and the Long QT syndrome. Also, the iPSC facilitated drug discovery services of iPSC based drug screening, iPSC based toxicity and efficacy analysis, iPSC derived the animal model, iPSC based target identification and the discovery of the effects of the drug on individual persons.
Our service is designed to accelerate the process of drug discovery and development by leveraging the unique capabilities of stem cells. This innovative service provides researchers with a powerful platform to study disease mechanisms, identify drug targets, and evaluate the efficacy and safety of novel pharmaceutical compounds.
Our service is dedicated to advancing research in the biopharmaceutical industry, providing essential tools and insights necessary for the development of effective therapeutics. By harnessing the power of stem cells, we aim to revolutionize the drug discovery process and contribute to the future of personalized medicine.
Our customized services according to the various situation of your projects, please feel free to contact us for professional consultation and welcome to get more information through the link below.
Below are the findings presented in the article related to stem cell facilitated drug discovery.
Yuta Koui et al. developed a culture system that generates quiescent hepatic stellate cells (qHSC cells) from human induced pluripotent stem cells (hiPSC), which can be transformed into activated HSC in culture. Using qHSC cells derived from an RFP reporter gene iPSC, they screened a repurposable chemical library and identified therapeutic candidates for the prevention of liver fibrosis.
Using this model, they demonstrated that A83-01 and ICG-001 inhibited HSC activation, and by screening drug relocation libraries, they identified compounds that inhibited HSC activation, among them the antimalarial drug artemisinin. They are currently conducting animal studies with another candidate compound identified by the drug screening system.
For Research Use Only. Not For Clinical Use.
